Correlation Between Climb Bio and Monte Rosa

Can any of the company-specific risk be diversified away by investing in both Climb Bio and Monte Rosa at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Climb Bio and Monte Rosa into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Climb Bio and Monte Rosa Therapeutics, you can compare the effects of market volatilities on Climb Bio and Monte Rosa and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Climb Bio with a short position of Monte Rosa. Check out your portfolio center. Please also check ongoing floating volatility patterns of Climb Bio and Monte Rosa.

Diversification Opportunities for Climb Bio and Monte Rosa

0.84

Correlation Coefficient

Climb Bio  Monte Rosa

Very poor diversification

The 3 months correlation between Climb and Monte is 0.84. Overlapping area represents the amount of risk that can be diversified away by holding Climb Bio and Monte Rosa Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Monte Rosa Therapeutics and Climb Bio is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Climb Bio are associated (or correlated) with Monte Rosa. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Monte Rosa Therapeutics has no effect on the direction of Climb Bio i.e., Climb Bio and Monte Rosa go up and down completely randomly.

Pair Corralation between Climb Bio and Monte Rosa

Given the investment horizon of 90 days Climb Bio is expected to generate 1.06 times more return on investment than Monte Rosa. However, Climb Bio is 1.06 times more volatile than Monte Rosa Therapeutics. It trades about 0.08 of its potential returns per unit of risk. Monte Rosa Therapeutics is currently generating about 0.03 per unit of risk. If you would invest  125.00  in Climb Bio on May 4, 2025 and sell it today you would earn a total of  20.00  from holding Climb Bio or generate 16.0% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Strong
Accuracy	100.0%
Values	Daily Returns

Climb Bio  vs.  Monte Rosa Therapeutics

Climb Bio

Risk-Adjusted Performance

Modest

Compared to the overall equity markets, risk-adjusted returns on investments in Climb Bio are ranked lower than 5 (%) of all global equities and portfolios over the last 90 days. In spite of very unfluctuating basic indicators, Climb Bio displayed solid returns over the last few months and may actually be approaching a breakup point.

Monte Rosa Therapeutics

Risk-Adjusted Performance

Insignificant

Compared to the overall equity markets, risk-adjusted returns on investments in Monte Rosa Therapeutics are ranked lower than 2 (%) of all global equities and portfolios over the last 90 days. In spite of rather unsteady basic indicators, Monte Rosa may actually be approaching a critical reversion point that can send shares even higher in September 2025.

Pair Trading with Climb Bio and Monte Rosa

The main advantage of trading using opposite Climb Bio and Monte Rosa positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Climb Bio position performs unexpectedly, Monte Rosa can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Monte Rosa will offset losses from the drop in Monte Rosa's long position.

The idea behind Climb Bio and Monte Rosa Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Commodity Channel module to use Commodity Channel Index to analyze current equity momentum.